TNGX

Tango Therapeutics is a drug company that develops cancer treatments targeting specific genetic mutations in tumors. The company is testing experimental medicines designed to work in patients whose cancers have particular genetic changes, such as mutations in genes called PRMT5 and STK11. Their drugs are still in early research stages, with some being tested in patients for pancreatic, lung, and brain cancers. The company was founded in 2017 and is based in Boston.